4001 Miranda Avenue
United States - Map
Affymax, Inc., a biopharmaceutical company, engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses. It offers OMONTYS (peginesatide) injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has a strategic collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize OMONTYS; and a license, manufacturing, and supply agreement with Nektar Therapeutics AL Corporation to manufacture, develop, and commercialize OMONTYS. Affymax, Inc. was founded in 2001 and is headquartered in Palo Alto, California.
|Affymax, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 9. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 7; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Ms. Karin L. Walker ,
Chief Accounting Officer and VP of Fin.
|Dr. Anne-Marie Duliege M.D., M.S.,
Chief Medical Officer
| J. Weston Rose ,
| Mark Thompson ,
Chief Financial Officer
|Dr. Tracy J. Dunn Ph.D., J.D.,
VP of Intellectual Property & Legal Affairs
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|